Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02817516 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants
A Phase 1 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02817516 is a Phase 1 study that was terminated before completion, run by Takeda. The registered enrollment target is 24 participants.
The verdict
NCT02817516, a Phase 1 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of multiple oral doses of TAK-828 in healthy participants.
Interventions
- DRUG Placebo
- DRUG TAK-828
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-06-30 |
| Est. Completion | 2016-08-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02817516
The ClinicalTrials.gov registry entry for NCT02817516 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02817516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02817516 about?
NCT02817516 is a clinical study titled "A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants". The purpose of this study is to evaluate the safety and tolerability of multiple oral doses of TAK-828 in healthy participants.
What is the current status of trial NCT02817516?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-06-30. Estimated completion is 2016-08-22.
What interventions are being tested in trial NCT02817516?
The interventions under investigation include: Placebo (DRUG), TAK-828 (DRUG).
Who is sponsoring clinical trial NCT02817516?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.